ArticleJournal of thoracic disease2026
Efficacy and safety of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small-cell lung cancer: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of anlotinib as a third-line or subsequent treatment for extensive-stage small-cell lung cancer (ES-SCLC) has been studied. The aim of this systematic review and meta-analysis was to evaluate the efficacy and safety of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of ES-SCLC. Methods: A systematic search was conducted on PubMed, Embase, Cochrane Library, and Web of Science databases. Studies investigating the efficacy of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of ES-SCLC were analysed. The results of these studies were summarized and meta-analyzed to calculate combined survival measures with 95% confidence intervals. Results: The meta-analysis included seven studies with a total of 519 cases. Regarding tumour response, the pooled objective response rate was 83.0%. Based on survival analysis, the pooled median progression-free survival and overall survival were 7.29 and 14.99 months, respectively. The most common treatment-related adverse events of anlotinib in combination with etoposide and platinum-based therapy were hypertension (all-grades: 28.4%, grade ≥3: 3.7%), decreased white blood cell count (all-grades: 27.2%, grade ≥3: 6.3%), and fatigue (all-grades: 27.2%, grade ≥3: 3.7%). Conclusions: This meta-analysis demonstrated that anlotinib in combination with etoposide and platinum-based regimens has potentially promising efficacy and safety in the first-line treatment of ES-SCLC. However, more randomized controlled trials are still needed to verify these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.